Articles related to BREAST CANCER

Temporary suspension of endocrine medication to seek pregnancy did not give a higher short-term risk of breast cancer events, including distant recurrence, than the external control cohort among select women with previous hormone receptor-positive (HR+) early breast cancer. Further investigation is required to ensure long-term safety.

This educational program aims to improve the knowledge and comprehension of the clinical trial and real-world evidence for the CDK4/6i class among HCPs. A greater percentage of patients with HR+/HER2 metastatic breast cancer (mBC) will have access to this therapeutic option by filling care gaps linked to CDK4/6i usage. The course will largely center on three (3) core learning areas: best practices in CDK4/6i therapy management, the significance of real-world evidence (RWE) in treatment decision-making, and CDK4/6i in mBC: indications, clinical data, and RWE.

Nanoformulations including liposomes, nanofibers, nanocapsules, dendrimers, and nanoparticles are currently being developed as solutions to remaining obstacles in cancer care. Some have already shown evidence of their ability to prevent cancer cell proliferation, lessen the risk of recurrence, minimize the chance of post-chemotherapy metastasis, and improve breast implants’ performance through better cell growth scaffolding.

The video features an interview with Dr. Jason Mouabbi, a surgical oncologist, who discusses the management of invasive lobular carcinoma (ILC), a type of breast cancer that is less common than other types. He explains that ILC is more challenging to diagnose than other breast cancers because it does not form a lump, but rather spreads in a linear fashion throughout the breast tissue. Dr. Mouabbi highlights the importance of early detection and screening for ILC. He then discusses the treatment options for ILC, which may include surgery, radiation therapy, and hormone therapy. He emphasizes the need for personalized treatment plans for each patient based on their specific case and individual needs. Dr. Mouabbi also talks about the potential role of neoadjuvant therapy in improving outcomes for patients with ILC. Overall, the video provides valuable insights into the management of ILC and highlights the importance of early detection and personalized treatment plans.

Women who are overweight have an increased risk of developing breast cancer. It is unknown whether prior obesity still carries a higher baseline risk of breast cancer in women who have shed a significant amount of weight as compared to peers without obesity. Researchers assembled a retrospective matched cohort study of 69,260 women who were followed up for 5 years after bariatric surgery or the index date (1/1/2010 – 12/31/2016) to see whether there is a residual risk of breast cancer among patients who undergo bariatric surgery due to prior obesity. According to the findings, bariatric surgery was linked to a lower risk of breast cancer in women with prior obesity that was equivalent to a woman with a BMI under 25, as well as a lower risk when compared to all groups with a BMI of 25 or higher.

The 49-year-old breast cancer specialist typically sees patients two days per week and spends the rest of her time pursuing other interests such as research and public policy. Dr. Patt has testified before the Texas legislature and Congress on issues ranging from legislation aimed at reducing prior authorization hurdles to the need to reform the 340B Drug Pricing Program to ensure that more federal funds reach underserved populations in her role as executive vice president of policy and strategy at Texas Oncology, a large community-based practice with more than 500 physicians.